Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Polo-like kinase 1 inhibitors - Cyclacel Pharmaceuticals

Drug Profile

Research programme: Polo-like kinase 1 inhibitors - Cyclacel Pharmaceuticals

Alternative Names: CYC 800 series; CYC800; Plk1 inhibitors - Cyclacel Pharmaceuticals; Polo-like kinase 1 inhibitors - Cyclacel Pharmaceuticals; Research programme: cell cycle modulators - Cyclacel Pharmaceuticals

Latest Information Update: 04 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Mitosis inhibitors; Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours
  • No development reported Cancer

Most Recent Events

  • 04 Apr 2018 Preclinical trials in Solid tumours in USA (PO), prior to April 2018 (Cyclacel pipeline, April 2018)
  • 28 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Scotland (PO)
  • 02 Apr 2012 Pharmacodynamics data from a preclinical study in Cancer presented at the 103rd Annual Meeting of the American Association for Cancer Research (AACR-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top